SAN DIEGO, Oct. 08, 2025 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark) (Nasdaq: AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics ...
Lantern Pharma Inc. (NASDAQ: LTRN), an AI-driven precision oncology company, today announced it has scheduled a Type C ...
SUNNYVALE, Calif., Aug. 21, 2024 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary ...
Expanded treatment in community settings will reduce patient burdenOption to redose patients granted in both Ntrust-1 and Ntrust-2 ...
Schedules FDA Type C Meeting For HARMONIC Trial Amendments. Lantern Pharma (NASDAQ: LTRN) announced it has scheduled a mid-May 2026 Type C meeting with the U.S. Food and Drug Administration to seek fe ...
Management described seeking an amendment to the VERSATILE-003 protocol to elevate progression-free survival (PFS) as a surrogate primary endpoint, in addition to maintaining median overall survival ...
Two classic translational blocks are compounded by an execution gap characterized by weak cross-functional mobilization, slow ...
23don MSN
PDS Biotech outlines accelerated regulatory timeline after VERSATILE-003 protocol amendment
Q4 2025 Management View Frank Bedu-Addo, President, CEO & Director, detailed that "the fourth quarter of 2025 capped a period of important progress for PDS Biotech, marked by meaningful advances ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results